Saturday, 31 October 2026European Markets

FERMENTALG Stock Tumbles Over 24% In Wednesday Trading Session

Loading stream...

(vianews) - on wednesday at 15:18 est, investors in fermentalg (cac 40: falg.pa) saw their stock dive by 24.92% to close at eur0.49 at 15:18 est - continuing its previous session's decline and marking another consecutive day of losses for this stock. meanwhile, cac 40 index also experienced a downward trend, falling 0.03% to eur7,945.86 following prior sessions of gains but did not extend to overall market performance; its decline did not extend as far; rather overall market closed with somewhat downward trends fermentalg closing price 65.42% below its 52 week high of eur1.87

about fermentalg

fermentalg sa, founded in 2009 and headquartered in libourne, france is a biotechnology company dedicated to microalgae research. they specialize in developing, producing and selling active ingredients derived from microalgae for applications across several industries such as food, health and the environment. fermentalg sa's innovative product offerings include dha origins(r) kalvea plus(r) everzuretm blue orginsaox/blue origin solutions as well as co2 capture systems in industries. their sustainable products meet growing global demands for sustainable and natural solutions while meeting growing global market demands for sustainable and natural solutions!

yearly analysis

fermentalg's stock (epa:alg) is currently trading at eur0.49, significantly below its 52-week high of eur1.87 but above its low point of eur0.21. this suggests investors may be bearish on short-term prospects while remaining bullish over longer term potential. as far as sales growth goes, fermentalg is expected to experience negative 14.4% sales growth this year before seeing strong rebound of 91.6% next year - giving investors insight into fermentalg's growth trajectory and potential returns in future returns.

technical analysis

fermentalg's stock has recently experienced a downward trend as its value sits below both its 50-day and 200-day moving averages, signalling potential bearish sentiment in the market. yet today it experienced an unexpected increase in volume trading - 8.63% higher than its average volume of 782,973 shares traded daily. fermentalg's volatility has fluctuated significantly in recent months, with its weekly, monthly and quarterly intraday variation averages being negative 1.97%, positive 2.56% and positive 6.29% respectively for intraday variations over this time frame. the highest amplitude of average volatility was observed at 2.33% weekly (9.35% monthly and 6.294% quarter). the stochastic oscillator, a widely utilized technical indicator, indicates that fermentalg's stock may currently be considered overbought (>=80), suggesting investors may be overly optimistic about its potential. as such, potential investors may wish to exercise caution and carefully consider their investment decisions prior to diving in headfirst.

quarter analysis

fermentalg's sales growth for the current quarter stands at an impressive 113.50%, signifying that revenue has significantly increased compared to its predecessor quarters. however, year-on-year quarterly revenue growth has dropped 55.4% and trailing twelve month revenue is 4.75m; suggesting that even though sales growth may be strong in this quarter and over the past year overall revenue has seen a noticeable decrease. investors should carefully assess both current quarter sales growth and overall revenue trend when assessing a company's financial performance and future growth potential. they may also wish to take other financial metrics and factors, such as profitability, cash flow and competitive landscape into consideration so as to make an informed investment decision.

equity analysis

earnings per share (eps) is a financial metric used to quantify how much profit a company's stock can produce per outstanding share, such as for fermentalg which currently generates losses of eur-0.24. return on equity (roe) is another financial metric used to gauge a company's profitability relative to shareholder investments in it. at fermentalg, its trailing 12-month roe is negative -24.52% indicating no profits being generated for shareholders. investors must exercise extreme caution when investing in companies generating losses or having a negative roe, as these indicators may suggest the company is struggling to generate profits from its operations. but before making an investment decision it's essential to carefully consider other financial metrics and qualitative factors; conducting further research and analysis on fermentalg's financial performance, industry trends, and competitive position might prove valuable in making more informed decisions.

more news about fermentalg (falg.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com